Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Lincoln National Corp

Lincoln National Corp boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 7.4% during the first quarter, Holdings Channel.com reports. The fund owned 5,406 shares of the medical research company’s stock after purchasing an additional 372 shares during the quarter. Lincoln National Corp’s holdings in Thermo Fisher Scientific were worth $3,193,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Palisade Capital Management LLC NJ lifted its stake in shares of Thermo Fisher Scientific by 1.4% during the first quarter. Palisade Capital Management LLC NJ now owns 10,762 shares of the medical research company’s stock worth $6,357,000 after purchasing an additional 145 shares in the last quarter. Forefront Analytics LLC lifted its stake in shares of Thermo Fisher Scientific by 3.9% during the first quarter. Forefront Analytics LLC now owns 528 shares of the medical research company’s stock worth $317,000 after purchasing an additional 20 shares in the last quarter. Checchi Capital Advisers LLC lifted its stake in shares of Thermo Fisher Scientific by 4.8% during the first quarter. Checchi Capital Advisers LLC now owns 3,304 shares of the medical research company’s stock worth $1,952,000 after purchasing an additional 150 shares in the last quarter. SeaBridge Investment Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 1.7% during the first quarter. SeaBridge Investment Advisors LLC now owns 9,662 shares of the medical research company’s stock worth $5,707,000 after purchasing an additional 164 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in shares of Thermo Fisher Scientific by 9.4% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 209,732 shares of the medical research company’s stock worth $123,878,000 after purchasing an additional 17,996 shares in the last quarter. Institutional investors and hedge funds own 87.48% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on TMO. SVB Leerink boosted their price objective on Thermo Fisher Scientific from $630.00 to $650.00 and gave the stock an “outperform” rating in a research note on Friday, July 29th. Barclays lifted their target price on Thermo Fisher Scientific from $630.00 to $685.00 and gave the stock an “overweight” rating in a research report on Monday, August 1st. Wells Fargo & Company lowered Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and dropped their target price for the stock from $605.00 to $525.00 in a research report on Monday, April 25th. Finally, Morgan Stanley lifted their target price on Thermo Fisher Scientific from $670.00 to $678.00 and gave the stock an “overweight” rating in a research report on Friday, July 29th. One analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $661.08.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $588.36, for a total value of $5,883,600.00. Following the completion of the sale, the chief executive officer now directly owns 183,373 shares in the company, valued at $107,889,338.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 814 shares of the company’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $597.24, for a total value of $486,153.36. Following the completion of the sale, the director now directly owns 15,807 shares in the company, valued at $9,440,572.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $588.36, for a total value of $5,883,600.00. Following the completion of the transaction, the chief executive officer now directly owns 183,373 shares in the company, valued at approximately $107,889,338.28. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,994 shares of company stock worth $29,033,170. Company insiders own 0.43% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $590.26 on Friday. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 0.69. The business has a 50 day moving average of $549.03 and a two-hundred day moving average of $557.79. Thermo Fisher Scientific Inc. has a 52 week low of $497.83 and a 52 week high of $672.34. The company has a market cap of $231.06 billion, a P/E ratio of 31.41, a PEG ratio of 1.84 and a beta of 0.83.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last issued its quarterly earnings data on Thursday, July 28th. The medical research company reported $5.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.92 by $0.59. The business had revenue of $10.97 billion during the quarter, compared to the consensus estimate of $9.95 billion. Thermo Fisher Scientific had a return on equity of 24.36% and a net margin of 17.37%. The business’s revenue was up 18.3% on a year-over-year basis. During the same period in the previous year, the firm posted $5.60 earnings per share. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 22.92 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 14th. Stockholders of record on Thursday, September 15th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $1.20 annualized dividend and a dividend yield of 0.20%. Thermo Fisher Scientific’s dividend payout ratio is presently 6.39%.

Thermo Fisher Scientific Company Profile

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.